UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 95

Sortiert nach

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing

Annals of oncology, 2015-06, Vol.26 (6), p.1216-1223

2015

Volltextzugriff (PDF)

Efficiency and power in genetic association studies

Nature genetics, 2005-11, Vol.37 (11), p.1217-1223

2005

Volltextzugriff (PDF)

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes

Annals of oncology, 2016-07, Vol.27 (7), p.1336-1341

2016

Volltextzugriff (PDF)

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

Journal of clinical pathology, 2014-09, Vol.67 (9), p.772-776

2014

Volltextzugriff (PDF)

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies

Gynecologic oncology, 2013-09, Vol.130 (3), p.554-559

2013

Volltextzugriff (PDF)

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias

Leukemia, 2017-01, Vol.31 (1), p.151-158

2017

Volltextzugriff (PDF)

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies

Journal of clinical pathology, 2014-11, Vol.67 (11), p.968-973

2014

Volltextzugriff (PDF)

Genome-wide discovery of transcriptional modules from DNA sequence and gene expression

Bioinformatics, 2003, Vol.19 Suppl 1 (suppl_1), p.i273-i282

2003

Volltextzugriff (PDF)

A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients

The pharmacogenomics journal, 2012-12, Vol.12 (6), p.484-488

2012

Volltextzugriff (PDF)

Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: Interim results for ARIEL2 clinical trial

Gynecologic oncology, 2015-05, Vol.138, p.4-4

2015

Volltextzugriff (PDF)

2651 Comprehensive genomic profiling (CGP) identifies unique and abundant clinically relevant genomic alterations in rare histologies of renal cell carcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S530-S530

2015

Volltextzugriff (PDF)

464 Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sensitive to MET inhibitors

European journal of cancer (1990), 2015-09, Vol.51, p.S99-S100

2015

Volltextzugriff (PDF)

2813 Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S562-S562

2015

Volltextzugriff (PDF)

2879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S583-S583

2015

Volltextzugriff (PDF)

2641 Comprehensive genomic profiling of advanced penile carcinoma suggests a high rate of clinically relevant genomic alterations

European journal of cancer (1990), 2015-09, Vol.51, p.S527-S527

2015

Volltextzugriff (PDF)

801 Therapeutically relevant extracellular domain mutations in ERBB2/HER2 are observed across multiple tumor types and are sssociated with major responses to anti-HER2 targeted therapies

European journal of cancer (1990), 2015-09, Vol.51, p.S133-S134

2015

Volltextzugriff (PDF)

3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S597-S597

2015

Volltextzugriff (PDF)

2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis

European journal of cancer (1990), 2015-09, Vol.51, p.S531-S531

2015

Volltextzugriff (PDF)

2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib

European journal of cancer (1990), 2015-09, Vol.51, p.S531-S532

2015

Volltextzugriff (PDF)

435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

European journal of cancer (1990), 2015-09, Vol.51, p.S90-S90

2015

Volltextzugriff (PDF)

414 Genomic profiling using a clinical next generation sequencing (NGS) assay reveals genomic alterations to guide targeted therapy in advanced neuroblastoma patients

European journal of cancer (1990), 2014-11, Vol.50, p.132-132

2014

Volltextzugriff (PDF)

415 Comprehensive next generation sequencing of solid tumors from 669 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations

European journal of cancer (1990), 2014-11, Vol.50, p.132-133

2014

Volltextzugriff (PDF)

250 Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes

European journal of cancer (1990), 2014-11, Vol.50, p.84-84

2014

Volltextzugriff (PDF)

Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

Blood cancer journal (New York), 2015-02, Vol.5 (2), p.e278-e278

2015

Volltextzugriff (PDF)

800 ORAL Comprehensive Next-Generation Sequencing (NGS) From Formalin-fixed NSCLC, CRC and Melanoma Cancer Tissues Identifies Novel Mutations With Potential Clinical Utility

European journal of cancer (1990), 2011, Vol.47, p.S95-S95

2011

Volltextzugriff (PDF)

1 – 25 von 95

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(91)

Publikationsform

Artikel
(94)
Berichte
(1)

Sprache

Englisch
(95)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(32)
Humans
(31)
Female
(21)
Hematology, Oncology And Palliative Medicine
(17)
Middle Aged
(17)
Oncology
(17)
Mutation
(15)
Aged
(14)
Male
(14)
Adult
(13)
High-Throughput Nucleotide Sequencing
(13)
Tumors
(11)
Genomics
(8)
Aged, 80 And Over
(7)
Antineoplastic Agents - Therapeutic Use
(7)
Genetic Predisposition To Disease
(7)
Gene Expression Profiling - Methods
(6)
Prognosis
(6)
Biological And Medical Sciences
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing

Efficiency and power in genetic association studies

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes

Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies

Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies

Genome-wide discovery of transcriptional modules from DNA sequence and gene expression

A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients

Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: Interim results for ARIEL2 clinical trial

2651 Comprehensive genomic profiling (CGP) identifies unique and abundant clinically relevant genomic alterations in rare histologies of renal cell carcinoma

464 Comprehensive genomic profiling of advanced cancers identifies MET exon 14 alterations that are sensitive to MET inhibitors

2813 Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma

2879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinoma

2641 Comprehensive genomic profiling of advanced penile carcinoma suggests a high rate of clinically relevant genomic alterations

801 Therapeutically relevant extracellular domain mutations in ERBB2/HER2 are observed across multiple tumor types and are sssociated with major responses to anti-HER2 targeted therapies

3007 Comprehensive genomic profiling characterizes the cpectrum of non-V600E activating BRAF alterations Including BRAF fusions in lung cancer

2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis

2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib

435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

414 Genomic profiling using a clinical next generation sequencing (NGS) assay reveals genomic alterations to guide targeted therapy in advanced neuroblastoma patients

415 Comprehensive next generation sequencing of solid tumors from 669 adolescents and young adults reveals a distinct spectrum of targetable genomic alterations

250 Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes

Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

800 ORAL Comprehensive Next-Generation Sequencing (NGS) From Formalin-fixed NSCLC, CRC and Melanoma Cancer Tissues Identifies Novel Mutations With Potential Clinical Utility

Suchergebnisse filtern